Tuesday, 27 April, 2021
10:00AM - 11:30 AM ET
American Society for Cellular and Computational Toxicology and European Society for Toxicology in Vitro
Marissa B. Kosnik, PhD, Technical University of Denmark
Shaun D. McCullough, PhD, US Environmental Protection Agency
Gary Marchant, PhD, JD, Sandra Day O’Connor College of Law, Arizona State U.
Kirk T. Hartley, JD, ToxicoGenomica and LSP Group LLC
It has been over a decade since the National Research Council described the vision for toxicity testing in the 21st century. Since that time, numerous initiatives have risen to the challenge resulting in high-throughput in vitro and computational new approach methodologies (NAMs) generating toxicity and exposure data, as well as predictive models, in chemical testing. These efforts have outlined guidance aimed at modernizing risk assessment to utilize data from NAMs; however, despite the advances of the last decade, few have actually been adopted by the risk assessment community. One of the challenges facing the use of NAMs in chemical risk assessment and regulation is their consideration in, and resilience to, legal challenges. Thus, their successful development and implementation in regulatory decision making relies on an underlying knowledge of the public health policy implications and legal precedents involved in the use of new and emerging technologies for regulatory decision making and product liability. This webinar will bring together two legal experts to discuss the balance between precedent and novel science in litigation ranging from regulatory policy to personal injury cases. Discussion will focus on several case studies including the use of NAMs under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), EPA Endocrine Disruptor Screening Program, Chlorine Chemistry Council v. EPA case (206 F.3d 1286 (D.C. Cir. 2000)), and others.